Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU focuses on safety and effectiveness of pandemic vaccines

This article was originally published in SRA

Executive Summary

As vaccination campaigns against pandemic flu get underway, the European regulatory and health authorities have laid out their strategy for monitoring the benefit:risk profiles of the various vaccines. The emphasis will be on the rapid detection and reporting of major safety issues such as life-threatening reactions and birth defects, as well as on the effectiveness and immunogenicity of the individual vaccines.

You may also be interested in...



Coronavirus Update: Supercomputing, Regulatory Flexibilities & Coordinating Supply Strategies

In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.

AbbVie Brings In Non-EU Kaletra To Bolster Dwindling French Supplies

The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.

Russia May Cap Drug Prices In Fight Against COVID-19

As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products. 

UsernamePublicRestriction

Register

PS114811

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel